Apeiron Biologics

Activities: Research & Development

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Expanding the medicinal chemist’s toolbox

Ray Boffey, Executive Director of Medicines Research at Domainex, explains the applications and benefits of fragment-based drug discovery, fragment hit expansion and the use of flow chemistry
Research & Development

Apeiron and Domainex partner to progress drug discovery

The companies have previously collaborated on hit identification, both fragment-based and virtual screening
Pharmaceutical

APEIRON appoints Peter Llewellyn-Davies as new CFO
Research & Development

Sanofi, Evotec and Apeiron Biologics to develop novel immuno-oncology treatments

Aim to bring together complementary expertise to identify and develop potential cancer treatments
Research & Development

Evotec and Apeiron establish pain alliance

Companies will identify small molecule modulators of DREAM
Subscribe now